Drug
Gonadotropin-Releasing Hormone clinical trials
Also written GnRH.
- studies test it
- 39
- open now
- 4
- in phase 3
- 7
- first study started
- 1994
Keep track of what changes. Save the Gonadotropin-Releasing Hormone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
36 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 1994 | 1 |
| 1998 | 1 |
| 1999 | 1 |
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 4 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 12
- Phase 3
- 7
- Phase 4
- 5
- No phase
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 34
Massachusetts General Hospital (9) · Ferring Pharmaceuticals (4) · University of Colorado, Denver (4) · Radiation Therapy Oncology Group (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Stephanie B. Seminara, MD (2) · University Reproductive Associates (1) · Hoffmann-La Roche (1)
Often tested with
Tested in the same studies.
KISS1 protein, human (6) · Paclitaxel (2) · Letrozole (2) · Gonadorelin diacetate tetrahydrate (2) · Estrogens (2) · Androgen Receptor Antagonists (2) · Ipatasertib (1) · Cobimetinib (1)
Studies
Open first, then newest update. How each study uses Gonadotropin-Releasing Hormone is read from its arms, and is right about nine times in ten.
Testing it · 39
- Autonomic and Renal Contributions to Hypertension With ADTRecruitingPhase 4Virginia Commonwealth UniversityNCT07848828Written as Gonadotropin Releasing Hormone Agonists (GNRH)
- Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPCRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT07476001Written as ADT with Luteinizing hormone-releasing hormone (LHRH) analog
- Controlled Ovarian Stimulation Versus Modified Natural Cycles in Poor RespondersRecruitingPhase 4University Hospital, GhentNCT04487925Written as A single Gonadotropin-Releasing Hormone (GnRH) antagonist corifollitropin alfa (CFA) stimulation
- GnRH Therapy on Cognition in Down SyndromeRecruitingPhase 2/3Nelly PitteloudNCT04390646Written as GnRH, gonadorelin acetate
- GnRH for Luteal Support in IVF/ICSI/FET CyclesActive, not recruitingPhase 4University Reproductive AssociatesNCT02357654Written as GnRH
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342Written as Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
- Contributions to Hypertension With Androgen Deprivation TherapyTerminatedPhase 4University of Colorado, DenverNCT05700903Written as Gonadotropin Releasing Hormone Agonists (GNRH)
- Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic HypogonadismCompletedPhase 2Stephanie B. Seminara, MDNCT04648969Written as GnRH
- Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate CancerCompletedNot applicableUniversity of British ColumbiaNCT00175383Written as luteinizing hormone-releasing hormone (LHRH) short acting or long acting
- Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate CancerActive, not recruitingPhase 3Radiation Therapy Oncology GroupNCT01368588Written as luteinizing hormone-releasing hormone (LHRH) agonist or antagonist
- Recall by Genotype: Neuropeptide StimulationTerminatedPhase 1Stephanie B. Seminara, MDNCT05901467Written as GnRH
- First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate CancerActive, not recruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05189457Written as Luteinizing Hormone Releasing Hormone
- A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod PumpWithdrawnPhase 1Ferring PharmaceuticalsNCT07152730Written as Lutrepulse
- Administration of Kisspeptin in Patients With HyperprolactinemiaCompletedPhase 2Massachusetts General HospitalNCT02956447Written as GnRH
- Neuropeptides in Human ReproductionCompletedPhase 1Massachusetts General HospitalNCT01952782Written as GnRH
- Kisspeptin Administration in the AdultCompletedPhase 1Massachusetts General HospitalNCT00914823Written as GnRH
- Kisspeptin in the Evaluation of Delayed PubertyCompletedPhase 1Massachusetts General HospitalNCT01438034Written as GnRH
- Elucidating Kisspeptin Physiology by Blocking Kisspeptin SignalingCompletedPhase 1Massachusetts General HospitalNCT01438073Written as GnRH
- Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)CompletedPhase 1Massachusetts General HospitalNCT00392756Written as gonadotropin releasing hormone (GnRH)
- Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With HypogonadismCompletedPhase 1Massachusetts General HospitalNCT00493961Written as gonadotropin releasing hormone (GnRH)
See all 39 studies that test Gonadotropin-Releasing Hormone →
Given in every arm · 22 — Gonadotropin-Releasing Hormone is usual care beside what is tested
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.RecruitingPhase 3MedSIRNCT06382948Written as Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
- The COSMYC Trial (COmbined Suppression of MYC)RecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06922318Written as Luteinizing hormone-releasing hormone (LHRH) analogue
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07142551Written as Luteinizing hormone-releasing hormone (LHRH) analogue
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06059118Written as Luteinizing hormone-releasing hormone (LHRH) analogue
- A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) StudyActive, not recruitingPhase 1Novartis PharmaceuticalsNCT06531499Written as Gonadotropin-releasing hormone (GnRH) analogues
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.Active, not recruitingPhase 1Novartis PharmaceuticalsNCT06379217Written as Gonadotropin-releasing hormone (GnRH) analogues
- An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASActive, not recruitingPhase 3Aragon Pharmaceuticals, Inc.NCT02531516Written as GnRH (agonist)
- Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of RecurringCompletedPhase 1/2NRG OncologyNCT04037254Written as Gonadotrophin Releasing Hormone
- Reprometabolic Syndrome Mediates Subfertility in ObesityActive, not recruitingNot applicableUniversity of Colorado, DenverNCT02653092Written as GnRH
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal WomenActive, not recruitingEarly Phase 1Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterNCT04037605Written as Gonadorelin (also known as Lutrepulse)
- Hormonal Mechanisms of Sleep Restriction - Axis StudyActive, not recruitingPhase 1Peter y. LiuNCT03142893Written as Gonadorelin
- Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADTTerminatedPhase 3Dana-Farber Cancer InstituteNCT03777982Written as LHRH Agonist or Antagonist
- To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)CompletedPhase 3Organon and CoNCT00702845Written as gonadatropin releasing hormone (GnRH) antagonist (ganirelix)
- Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)Status unknownPhase 2Dana-Farber Cancer InstituteNCT03141671Written as GnRH
- Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00587431Written as GnRh (Leuprolide)
- Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone TherapyCompletedPhase 3Radiation Therapy Oncology GroupNCT00329797Written as LHRH
- Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With HypogonadismTerminatedPhase 2Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NCT00064987Written as gonadotropin releasing hormone (GnRH)
- Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate CancerStatus unknownNot applicableTianjin Medical University Cancer Institute and HospitalNCT02605226Written as luteinizing-hormone releasing-hormone (LHRH) agonist
- Endocrine Therapy With or Without Cryoablation for Stage IV Prostate CancerStatus unknownNot applicableTianjin Medical University Cancer Institute and HospitalNCT02615223Written as luteinizing-hormone releasing-hormone (LHRH) agonist
- External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate CancerTerminatedPhase 2/3Proton Collaborative GroupNCT01603420Written as Luteinizing hormone-releasing hormone (LHRH)
Showing 20 of 22.
Codes
What other systems call Gonadotropin-Releasing Hormone · ClinicalTrials.gg INT007734
Also registered as gonadorelin (UNII 9O7312W37G · RxNorm 6384) and gonadorelin acetate (UNII 2RG1XQ1NYJ · RxNorm 204193).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.